3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
OTHER_GOV
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
157
Lung Neoplasms
73
Small Cell Lung Carcinoma
52
Neoplasms
8
Melanoma
8
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Mesothelioma, Malignant
6
Mesothelioma
6
Colorectal Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Respiratory Tract Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Diseases
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Bronchogenic
3
Bronchial Neoplasms
3
Adenocarcinoma of Lung
3
Interventions
pembrolizumab
44
Carboplatin
17
Pemetrexed
14
Paclitaxel
13
Cisplatin
13
lenvatinib
5
Etoposide
5
Docetaxel
5
epacadostat
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
durvalumab
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
olaparib
2
Saline Solution
2
Immune Checkpoint Inhibitors
2
Dexamethasone
2
Acetaminophen
2
sacituzumab govitecan
1
ribociclib
1
patritumab deruxtecan
1
osimertinib
1
etoposide phosphate
1
efineptakin alfa
1
cemiplimab
1
camrelizumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
durvalumab
×
Thoracic
×
Clear all
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled
NCT07192926
2026-02-20
SARCO-CTI
Ankara Etlik City Hospital
Completed
131 enrolled
NCT05298423
2025-08-01
KEYVIBE-006
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
611 enrolled